Effect of Claro on adrenal function in clinically healthy dogs

Study objectives
The purpose of this study is to determine if the application of a commonly used and widely available ear medication (Claro) for dogs, which contains a potent topical steroid, decreases natural steroid hormone production, and if so, for how long, in otherwise healthy dogs diagnosed with otitis externa.

Inclusion criteria
Dogs must be:
• 8 months - 6 years of age
• Maximum weight of 20 kg
• Bilateral otitis externa preferred

Exclusion criteria
• Use of corticosteroids (topical or systemic) within 3 months prior to entry
• Clinical suspicion of Pseudomonas otitis which would not respond to Claro administration
• A ruptured tympanic membrane as assessed on otoscopy
• Pyoderma
• Generalized pruritus
• Systemic illness

Study benefits
Involvement in the study requires 2-3 visits on days 0, 28, and 42 (if needed) within a 4-6 week period.
Benefits provided at no cost for qualifying dogs include:
• Claro otic medication
• ACTH stimulation testing
• Otoscopy and otic cytology at each visit
• Visits directly related to the study
Any additional costs will be discussed with client before they are required.

Contact information
Dr. Sarah Hoppers
saremorr@vols.utk.edu | 865-974-8387
Dr. Elizabeth Drake
elizabethdrake@tennessee.edu | 865-974-8387
Gina Galyon, LVMT (clinical trial coordinator)
ggalyon@utk.edu | 865-755-8151

IACUC PROTOCOL: 2674-0119